Multinational phase 2 study of atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases

Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. The multinational phase 2 TRICOTEL study evaluated atezolizumab in combination with cobimetinib or with vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. The study found intracranial activity of atezolizumab plus vemurafenib and cobimetinib in patients with BRAF^V600-mutated melanoma with CNS metastases. Treatment-related serious adverse events occurred in 23% of these patients.